The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

[1]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[2]  C. Broeckhoven,et al.  Potent amyloidogenicity and pathogenicity of Aβ43 , 2011, Nature Neuroscience.

[3]  M. Simpson,et al.  PSENEN and NCSTN mutations in familial hidradenitis suppurativa (Acne Inversa). , 2011, The Journal of investigative dermatology.

[4]  Klaus P. Ebmeier,et al.  The influence of ApoE4 on clinical progression of dementia: a meta‐analysis , 2011, International journal of geriatric psychiatry.

[5]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[6]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[7]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[8]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[9]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[10]  A. Mammen,et al.  Large Quantities of Aβ Peptide Are Constitutively Released during Amyloid Precursor Protein Metabolism in Vivo and in Vitro* , 2011, The Journal of Biological Chemistry.

[11]  F. Lopera,et al.  Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study , 2011, The Lancet Neurology.

[12]  M. Weiner,et al.  Developing a global strategy to prevent Alzheimer’s disease: Leon Thal Symposium 2010 , 2011, Alzheimer's & Dementia.

[13]  W. Thies.  Stopping a thief and killer: Alzheimer's disease crisis demands greater commitment to research , 2011, Alzheimer's & Dementia.

[14]  Todd E. Golde,et al.  Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.

[15]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[16]  Martin Eichner,et al.  Long-Term In Vivo Imaging of β-Amyloid Plaque Appearance and Growth in a Mouse Model of Cerebral β-Amyloidosis , 2011, The Journal of Neuroscience.

[17]  Michele Vendruscolo,et al.  Amyloid-like Aggregates Sequester Numerous Metastable Proteins with Essential Cellular Functions , 2011, Cell.

[18]  Baoxi Wang,et al.  γ-Secretase Gene Mutations in Familial Acne Inversa , 2010, Science.

[19]  S. MacDonald,et al.  Onset and Rate of Cognitive Change Before Dementia Diagnosis: Findings From Two Swedish Population-Based Longitudinal Studies , 2010, Journal of the International Neuropsychological Society.

[20]  Inna Kuperstein,et al.  Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio , 2010, The EMBO journal.

[21]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[22]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[23]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[24]  Seth Love,et al.  Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease , 2010, PloS one.

[25]  K. Blennow,et al.  Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease , 2010, Alzheimer's & Dementia.

[26]  B. Winblad,et al.  Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.

[27]  Todd E. Golde,et al.  Targeting Aβ and tau in Alzheimer's disease, an early interim report , 2010, Experimental Neurology.

[28]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[29]  B. Strooper.  Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process , 2010 .

[30]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[31]  K. Blennow,et al.  Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease , 2010, Molecular Neurodegeneration.

[32]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[33]  Carol Brayne,et al.  Age, neuropathology, and dementia. , 2009, The New England journal of medicine.

[34]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[35]  Y. Ihara,et al.  γ-Secretase: Successive Tripeptide and Tetrapeptide Release from the Transmembrane Domain of β-Carboxyl Terminal Fragment , 2009, The Journal of Neuroscience.

[36]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[37]  M. Viitanen,et al.  Comparison of Aβ levels in the brain of familial and sporadic Alzheimer's disease , 2009, Neurochemistry International.

[38]  Mary Sano,et al.  Current Alzheimer's disease clinical trials: Methods and placebo outcomes , 2009, Alzheimer's & Dementia.

[39]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[40]  Yan Wang,et al.  Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice , 2009, The Journal of Neuroscience.

[41]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[42]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[43]  B. Winblad,et al.  Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains , 2009, Journal of neurochemistry.

[44]  Randall J Bateman,et al.  A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system , 2009, Annals of neurology.

[45]  C. Robinson,et al.  Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. , 2009, Nature chemistry.

[46]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[47]  B. Hyman,et al.  Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575 , 2009, Molecular Neurodegeneration.

[48]  Frederico A. C. Azevedo,et al.  Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled‐up primate brain , 2009, The Journal of comparative neurology.

[49]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[50]  Lippincott Williams Wilkins,et al.  Survival in Alzheimer disease: A multiethnic, population-based study of incident cases , 2009, Neurology.

[51]  M. Stoeckli,et al.  Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition , 2008, Journal of Pharmacology and Experimental Therapeutics.

[52]  K. Lapane,et al.  Dementia of the Alzheimer type. , 2008, Epidemiologic reviews.

[53]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[54]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[55]  A. Korczyn.  The amyloid cascade hypothesis , 2008, Alzheimer's & Dementia.

[56]  F. Schmidt.  Meta-Analysis , 2008 .

[57]  Manuel Buttini,et al.  Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice* , 2007, Journal of Biological Chemistry.

[58]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[59]  M. Wolfe.  When loss is gain: reduced presenilin proteolytic function leads to increased Aβ42/Aβ40 , 2007 .

[60]  B. Strooper.  Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. , 2007 .

[61]  D. Dickson,et al.  Aβ40 Inhibits Amyloid Deposition In Vivo , 2007, The Journal of Neuroscience.

[62]  R. J. Kelleher,et al.  The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism , 2007, Proceedings of the National Academy of Sciences.

[63]  R. Hepler,et al.  Solution State Characterization of Amyloid β-Derived Diffusible Ligands , 2006 .

[64]  Tracy M. Brown,et al.  Concentration-Dependent Modulation of Amyloid-β in Vivo and in Vitro Using the γ-Secretase Inhibitor, LY-450139 , 2006, Journal of Pharmacology and Experimental Therapeutics.

[65]  D. Walsh,et al.  Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.

[66]  M. Carrillo,et al.  Optimal design of clinical trials for drugs designed to slow the course of Alzheimer’s disease , 2006, Alzheimer's & Dementia.

[67]  C. van Broeckhoven,et al.  Mean age‐of‐onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40 , 2006, Human mutation.

[68]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[69]  George D. Mellick,et al.  Parkinson's Disease in Relation to Pesticide Exposure and Nuclear Encoded Mitochondrial Complex I Gene Variants , 2006, Journal of biomedicine & biotechnology.

[70]  D. Dickson,et al.  β-Amyloid Degradation and Alzheimer's Disease , 2006, Journal of biomedicine & biotechnology.

[71]  C. Glabe.  Common mechanisms of amyloid oligomer pathogenesis in degenerative disease , 2006, Neurobiology of Aging.

[72]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[73]  Y. Ihara,et al.  DAPT-Induced Intracellular Accumulations of Longer Amyloid β-Proteins: Further Implications for the Mechanism of Intramembrane Cleavage by γ-Secretase† , 2006 .

[74]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[75]  B. Strooper,et al.  Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms , 2006, Journal of neurochemistry.

[76]  M. Frosch,et al.  The Cerebral β‐Amyloid Angiopathies: Hereditary and Sporadic , 2006 .

[77]  J. Morris,et al.  Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. , 2005, Archives of neurology.

[78]  H. Lester,et al.  Open access, freely available online PLoS MEDICINE Persistent Amyloidosis following Suppression of Ab Production in a Transgenic Model of Alzheimer Disease , 2022 .

[79]  J. Hardy,et al.  Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration. , 2005, Biochemical Society transactions.

[80]  Marc Verny,et al.  [Survival after initial diagnosis of Alzheimer disease]. , 2005, Psychologie & neuropsychiatrie du vieillissement.

[81]  S. DeKosky,et al.  Alzheimer disease and mortality: a 15-year epidemiological study. , 2005, Archives of neurology.

[82]  R. Mohs.  The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials , 2005, Genes, brain, and behavior.

[83]  S. Hébert,et al.  Differential contribution of the three Aph1 genes to γ-secretase activity in vivo , 2005 .

[84]  Nick C Fox,et al.  The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort. , 2004, Archives of neurology.

[85]  P. May,et al.  P2-053 Reduced β-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months , 2004, Neurobiology of Aging.

[86]  D. Holtzman,et al.  In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.

[87]  Kenneth S. Kosik,et al.  Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred , 2003 .

[88]  G. Silverberg,et al.  Alzheimer's disease, normal‐pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis , 2003, The Lancet Neurology.

[89]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[90]  A. Delacourte,et al.  Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease , 2002, Neurology.

[91]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[92]  R. Brookmeyer,et al.  APOE genotype and survival in men and women with Alzheimer’s disease , 2002, Neurology.

[93]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[94]  D. Holtzman,et al.  Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.

[95]  S. Lovestone,et al.  The clinical phenotype of familial and sporadic late onset Alzheimer's disease , 2002, International journal of geriatric psychiatry.

[96]  C. Holmes,et al.  Genotype and phenotype in Alzheimer's disease , 2002, British Journal of Psychiatry.

[97]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[98]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[99]  E. Boerwinkle,et al.  Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. , 2000, Genome research.

[100]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[101]  J R Ghilardi,et al.  Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. , 2000, Biochemistry.

[102]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[103]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[104]  D. Selkoe,et al.  Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme , 2000, The Journal of Neuroscience.

[105]  J. Tang,et al.  Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[106]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[107]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[108]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[109]  David G. Tew,et al.  Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.

[110]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[111]  H. Vanderstichele,et al.  Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[112]  S. Gauthier,et al.  Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. , 1999, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[113]  H. Vinters,et al.  Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. , 1999, Biochemistry.

[114]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[115]  B. Yankner,et al.  Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[116]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[117]  K. Welsh-Bohmer,et al.  APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease , 1998, Nature Genetics.

[118]  Steven D. Edland,et al.  Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease , 1998, Neurology.

[119]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[120]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[121]  Hugo Vanderstichele,et al.  Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.

[122]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[123]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[124]  C. Haass,et al.  Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing. , 1997, Genes and function.

[125]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[126]  T. Iwatsubo,et al.  Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain , 1996, Neuroscience Letters.

[127]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[128]  B. O’Donnell,et al.  Rate of Progression in Familial Alzheimer's Disease , 1996, Journal of geriatric psychiatry and neurology.

[129]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[130]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[131]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[132]  S. Younkin,et al.  Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain , 1995, The Journal of Biological Chemistry.

[133]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[134]  D. Mann,et al.  Dominant and differential deposition of distinct β-amyloid peptide species, Aβ N3(pE), in senile plaques , 1995, Neuron.

[135]  J Carter,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[136]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[137]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[138]  H. Vinters,et al.  Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[139]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[140]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[141]  Eka Swadiansa.  The hypothesis , 1990 .

[142]  L. Jarvik,et al.  About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson) , 1986, Alzheimer disease and associated disorders.

[143]  B. Reisberg,et al.  Dementia: a systematic approach to identifying reversible causes. , 1986, Geriatrics.

[144]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[145]  B. de Strooper.  Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. , 2010, Physiological reviews.

[146]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[147]  B. Strooper,et al.  Presenilins: members of the gamma-secretase quartets, but part-time soloists too. , 2008, Physiology.

[148]  C. van Broeckhoven,et al.  Genetics and pathology of alpha-secretase site AbetaPP mutations in the understanding of Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[149]  J. Duncan,et al.  The choroid plexus-cerebrospinal fluid system: from development to aging. , 2005, Current topics in developmental biology.

[150]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[151]  G. Koelsch,et al.  Human aspartic protease memapsin 2 cleaves the b-secretase site of b-amyloid precursor protein , 2000 .

[152]  E B Larson,et al.  Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. , 1998, Neurology.

[153]  P Leber,et al.  Slowing the progression of Alzheimer disease: methodologic issues. , 1997, Alzheimer disease and associated disorders.

[154]  S H Ferris,et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.

[155]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.

[156]  J Huff,et al.  Diagnostic criteria for dementia in clinical trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. , 1997, Alzheimer disease and associated disorders.

[157]  J. Morris,et al.  Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) , 1997 .

[158]  H. Braak,et al.  Staging of Alzheimer-related cortical destruction. , 1997, International psychogeriatrics.

[159]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[160]  G. Milliken.  Methodologic issues. , 1995, Statistics in medicine.

[161]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[162]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[163]  1 The GloBAl eCoNomiC impACT oF demeNTiA Alzheimer ’ s diseAse internAtionAl World Alzheimer report 2010 the GlobAl economic impAct of dementiA , 2022 .